Overview

A Study of LY2439821 in Rheumatoid Arthritis

Status:
Completed

Trial end date:
2013-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of LY2439821 subcutaneously administered for 48 weeks in Japanese participants with rheumatoid arthritis who have completed Study I1F-JE-RHAL (NCT01253265).

Phase:

Phase 1

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Ixekizumab